2 ‘secret’ pharma stocks I’m considering buying right now

G A Chester reveals two under-the-radar pharma stocks that could deliver market-trumping returns.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The AIM market isn’t the obvious place to look for a low-risk pharmaceuticals stock, but Alliance Pharma (LSE: APH) is an exception to the rule. Its market capitalisation at a share price of 67p is over £300m and I see it as a very attractive business to invest in.

Highly effective and productive

Alliance was founded in 1996 and entered into a fostering arrangement with Novartis, under which it took over the marketing and distribution of 16 of the Swiss giant’s speciality prescription brands. It’s gone on to acquire or license the rights to 90 established pharmaceutical and consumer healthcare products from various companies.

Alliance’s low-risk business model has been highly effective and productive. Management advised in a recent pre-close trading update that annual revenue broke through £100m for the first time in 2017.

Robust growth

The company continues to expand its portfolio under founder and chief executive John Dawson and a board of fellow industry veterans. Two recent product acquisitions — Vamousse (head lice) from TyraTech and Ametop (local anaesthetic gel) from Smith & Nephew — will be immediately earnings enhancing.

Revenue for 2018 is forecast to increase 14% to £118m, with earnings and dividends similarly increasing to 4.8p and 1.5p. The forward price-to-earnings ratio of 14 and dividend yield of 2.2% represent great value to me for a well-managed business with a history and outlook of robust growth. As such, I rate the stock a ‘buy’.

Seductive stories

Optibiotix (LSE: OPTI) is a rather different investment proposition to Alliance and also a more speculative one. Generally, I steer well clear of companies that are at the pre-revenue (or negligible revenue) stage, as a large proportion of them disappoint. But occasionally one pops up where I see genuine potential for high rewards.

Of course, all such stocks have a seductive ‘story’ — Optibiotix’s is products that modulate the human microbiome to tackle such things as obesity, high cholesterol and diabetes — but it takes more than a seductive story for me to consider it a potential investment.

Crucial questions

There are a number of crucial questions to which I must feel able to give an affirmative answer. These include: Are the directors of the company experienced and credible? Is its technology credible, patent protected and so on? Does it have a sound commercial strategy for bringing its products to market?

For me, Optibiotix ticks all the boxes for these sorts of question. Of course, there’s then another crucial question: How much would I be willing to pay for the shares?

Multibagger potential

When I wrote about the company last year, the shares were trading at 68.5p and the market capitalisation was £54m. This is the sort of level from which it’s possible to envisage a serious multi-bagger, if the company were to deliver on its potential. And it looks more attractive today, because the shares have slipped below 60p in the recent market wobble taking the market cap to £46m.

Optibiotix is the sort of stock I’d only take a very small position in as part of a diversified portfolio — sized to have a good impact on returns if hugely successful and a tolerable level of negative impact if a total write-off. In short, I rate the stock a ‘buy’ at the high-risk end of the spectrum.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Engineer Project Manager Talks With Scientist working on Computer
Investing Articles

I reckon this S&P 500 stock could be among the best shares for me to buy today

This S&P 500 monopoly stock's trading at a 30% discount to its historical valuation just as growth could be about…

Read more »

Investing Articles

A ridiculously cheap FTSE 250 stock to buy today?

The FTSE 250's rising by double-digits, but this stock's seemingly falling behind despite higher cash flows and dividends. At a…

Read more »

Investing Articles

The FTSE 100’s trading near a 52-week high! I’m still looking to buy

The FTSE 100's slowly making its way towards record highs, but there are still dirt cheap buying opportunities to discover…

Read more »

Smiling senior white man talking through telephone while using laptop at desk.
Investing Articles

1 surging stock I think could gatecrash the FTSE 100 in 2025!

Royston Wild reckons this FTSE 250 share is heading all the way to the Footsie. Here he explains why it's…

Read more »

artificial intelligence investing algorithms
Investing Articles

Should I buy skyrocketing Palantir stock for my ISA in 2025?

This red-hot artificial intelligence share has even outperformed Nvidia so far this year. Is it finally time I added it…

Read more »

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

2 of my favourite UK growth shares this December!

These FTSE 250 growth shares offer excellent value right now. Here's why I'll buy them for my portfolio if the…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

10% dividend growth! 2 FTSE 100 stocks tipped to supercharge cash payouts

These FTSE 100 stocks have strong records of dividend growth. And they're expected to keep on delivering, as Royston Wild…

Read more »

Investing Articles

Down 17% in a month and yielding 7.39%! Is this FTSE 100 share a screaming buy for me?

When Harvey Jones bought Taylor Wimpey last year he thought this FTSE 100 share was a brilliant long-term buy-and-hold. Has…

Read more »